Twitter Twitter Facebook Facebook Linked In Linked In Zone In Zone In Google Plus Zone In

Research Update

High Affinity RNA Aptamers Target NMDA Receptors, Boasting Specificity, Flexibility and Economical Advantages

Conditions of the central nervous system are difficult to treat, particularly those targeting post-synaptic receptors. One such receptor, the NMDA receptor is known to trigger long-lasting changes in synapses. NMDA receptor-dependent synaptic plasticity is important not only in physiological functions such as learning and memory, but also in unwanted pathological conditions such as Parkinson’s disease and chronic pain. Tight regulation of the receptors is crucial for maintaining proper function. Furthermore, subunits of the post-synaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and kainate receptor have similar homology, making target discernment even more challenging. To address these challenges, Lee et al. have turned to aptamers.

Read More


Stop by our poster Pushing the Limits of PCR at TRI-CON to speak with CleanAmp™ co-inventor Dr. Zon.

Featured Product
RNA Library for RNA Aptamer Selection

GMP Manufacturing
Ready to take your aptamer, oligo or mRNA into early phase clinical studies? Learn how we can save you time and money.
Your Aptamer Reagent Partner

Let our expertise in modified nucleic acid chemistry and commitment to manufacturing the highest quality reagents support your aptamer research.

Stocked Random Libraries
Modified Nucleoside Triphosphates
Aptamer Synthesis & Conjugation





Blog Post

Back to the Future with RNA and XNA
Back to the Future
  • The Prebiotic ‘RNA World’ Predates our DNA-Based Genetics
  • What About Other Life-Forming Nucleic Acid (XNA)?
  • New Research Discovers Synthetic XNA Providing Possible Clues

The metaphorical connection between Back to the Future and nucleic acids comes from currently captivating theories about RNA preceding DNA in molecular evolution of life, and—more intriguingly—whether XNA played a primordial role back then, or might in the future. Read More

A Fast, Cost-Effective Approach to Therapeutic GMP Manufacturing

We've combined our nucleic acid modification expertise with a state-of-the-art facility to now offer therapeutic GMP manufacturing. With a wide variety of available synthesis scales, you can get just the amount of material you need for IND-enabling tox studies and early phase clinical trials. We can deliver your therapeutic oligo, mRNA or nucleotide quickly and at an affordable price regardless of the scale.

State-of-the-Art Facility

Our new, 2,000 square foot GMP facility is dedicated to manufacturing therapeutic products and is ISO certified by Lloyd’s Register. The controlled labs feature:

  • Validated ISO Class 7 and Class 8 clean rooms
  • Compliance with ICH Q7, CFR 210 and other phase-appropriate GMPs
  • Single pass, HEPA filtered air system
  • Routine monitoring for temperature, pressure, humidity and particle count
  • Fully gowned staff Facilities, processes, equipment and computerized systems are validated (IQ/OQ) and maintained in a validated state
Learn More
Request a Consultation

© 2015 TriLink BioTechnologies, Inc. | All Rights Reserved